Generic for Ozempic Approved in Canada

A New Era for GLP-1 Drug Affordability in Canada

In a landmark development for Canadian drug plans, Health Canada has approved the first generic version of Ozempic (semaglutide). Canada is now the first G7 country to authorize a generic alternative to the widely used GLP-1 therapy for type 2 diabetes, with additional generic submissions already under review.

For group benefits plan sponsors, this signals a meaningful opportunity to manage one of the fastest-growing and highest-cost drug categories.

Why This Matters: GLP-1 Drugs Are a Cost Pressure

GLP-1 medications like Ozempic have seen explosive demand due to their effectiveness in managing diabetes, and, increasingly, their off-label use in weight management.

• Brand-name Ozempic costs roughly $200–$450 per month in Canada (per a recent Global News article)
• Annual costs can exceed $5,000 per claimant depending on dosage and indication
• GLP-1 drugs are a maintenance medication meaning their usage is generally an annual recurring cost for each member

For employer-sponsored plans, even modest utilization can materially impact trend and sustainability.

Expected Savings: What Generics Change

The introduction of generic semaglutide has the potential to significantly bend the cost curve. More broadly, generic drugs in Canada are often 45% to 90% cheaper than brand-name equivalents.

The expected impact for plan sponsors:

• Early-stage savings may be modest (15–25%)
• Medium-term savings could exceed 50–65%
• Long-term savings (when several generics are available) could approach 65%+

With multiple manufacturers already in the pipeline, pricing pressure is expected to accelerate over the next 12–24 months.

‍Savings Are Not Automatic

Despite the headline opportunity, plan sponsors will not fully realize these savings without the appropriate drugs management strategies included in their benefits program.

This is where Joseph Partners can help.  We spend considerable time with clients working on benefit plan strategies that reflect not only company philosophies but also capitalize on opportunities in the market to generate cost savings for plan sponsors.

Bottom Line

The approval of generic semaglutide is a significant step forward, but plan design will determine whether savings are realized or missed.

Employers that proactively implement mandatory generic substitution and lowest equivalent pricing will be well positioned to capture the full financial benefit of this shift.

Those that don’t may find that despite lower-priced alternatives entering the market, their drug spend doesn’t shift too much.